Managed Access Programmes
The FarmaMondo Group supports biopharmaceutical companies in the supply of products to patients in markets where they have not yet been launched commercially. We design and implement Managed Access Programmes (MAP), including Named Patient Programmes (NPP) services, in more than 80 markets.
While the market access plans of research-based pharmaceutical companies may not cover all countries equally, their patient-centric approach also allows access for patients with unmet medical needs in countries where their therapies are not yet commercially available.
It may take years before therapies are approved for commercial supply in certain countries, and patients cannot always wait that long. During this lag time, FarmaMondo responds to global healthcare professionals’ requests to access such therapies and supplies them with country-specific named patient regulatory routes.
The Group offers both paid access and pro-bono (compassionate) access programmes through a comprehensive service package with a fair financial structure and flexible terms.
The Group currently operates the following programmes across various geographic regions. For more information, please contact FarmaMondo offices in your region.
|Therapeutic Area||Indications||Geographical Scope|
|Cardiovascular||Acute Ischemic Stroke||Targeted regions/countries|
|Acute Myocardial infarction||Targeted regions/countries|
|Arterial Hypertension||Targeted regions/countries|
|Idiopathic or heritable pulmonary arterial hypertension (PAH)||Targeted regions/countries|
|Hematology Orphan||Paroxysmal Nocturnal Hemoglobinuria (PNH)||Targeted regions/countries|
|Infectious Diseases & Virology||Viral CMV retinitis; Mucocutaneous Acyclovir Resistant HSV Infections||Targeted regions/countries|
|Metabolic Disease Orphan||Wilson's disease (orphan)||Targeted regions/countries|
|Congenital Generalized Lipodystrophy||Targeted regions/countries|
|Homozygous Familial Hypercholesterolemia||Targeted regions/countries|
|Alagille syndrome (ALGS)||Targeted regions/countries|
|Progressive familial intrahepatic cholestasis (PFIC)||Targeted regions/countries|
|Nephrology Orphan||Atypical Hemolytic Uremic Syndrome (aHUS)||Global|
|Neurology Orphan||Duchenne Muscular Dystrophy||Targeted regions/countries|
|Oncology||Epithelial ovarian cancer / fallopian tube cancer||Targeted regions/countries|
|Chemotherapy induced neutropenia||Targeted regions/countries|
|Onco-haematology||Acute Promyelocytic Leukemia||Targeted regions/countries|
|Multiple myeloma, melanoma, amyloidosis, sarcoma||Targeted regions/countries|
|Acute Lymphoblastic Leukemia (ALL)||Global|
|Ophthalmology Orphan||Neurotrophic Keratitis||Targeted regions/countries|
|Pediatric Oncology||Neuroblastoma||Targeted regions/countries|
|Transplantation||Conditioning agent for bone marrow transplantation||Targeted regions/countries|